- Awards
- 24
- Value outside frameworks
- -
- Framework places
- 6
- Shared awards
- 17
Values exclude VAT where the notices give it, and only values in pounds are added up. A framework place carries the framework's whole ceiling, shared with the other suppliers on it, so framework places are counted rather than added up; so are awards made to several suppliers together.
Awards
| Procurement | Buyer | Value | Date |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 Lot 1 framework |
NHS England |
£665,389,588 |
6 Jul 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 Lot 2 framework |
NHS England |
£18,903,212 |
6 Jul 2026 |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 Lot 1 framework |
NHS England |
£665,389,588 |
15 Jun 2026 |
| Transitional Drugs 7 shared |
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) |
£16,804,001 |
4 Jun 2026 |
| Ustekinumab shared |
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) |
£6,532,463 |
4 Jun 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 Lot 1 framework |
NHS England |
£813,863,584 |
1 Jun 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 Lot 2 framework |
NHS England |
£18,903,212 |
1 Jun 2026 |
| Transitional Drugs 6 shared |
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) |
£1,637,726 |
29 Jan 2026 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 framework |
NHS England |
£15,059,000 |
30 Sep 2025 |
| NHS Framework, North of England, Branded Medicines-Tranche A and Annual Tranche |
NHS England |
- |
11 Feb 2021 |
| NHS Framework for the Midlands and East, Branded Medicines - Tranche B shared |
NHS England |
£228,156,862 |
25 Jan 2021 |
| NHS Framework for the NHS London Region, Branded Medicines - Tranche A shared |
NHS England |
£191,062,951 |
17 Jun 2020 |
| NHS Framework Agreement - North of England - Tranche B shared |
NHS England |
£205,535,556 |
13 Feb 2020 |
| NHS Midlands and East Branded Medicines - Tranche A shared |
NHS England |
£418,787,000 |
15 Jan 2020 |
| NHS South of England Branded Medicines - Tranche A - Contracts Finder Award Notice shared |
NHS England |
£188,004,961 |
1 Aug 2019 |
| NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder Opportunity shared |
NHS England |
£251,930,337 |
5 Jul 2019 |
| NHS Framework agreement for Branded Medicines - North of England - Tranche A shared |
NHS England |
£204,551,038 |
18 Feb 2019 |
| NHS England - Midlands and East Branded Medicines - Tranche B shared |
NHS England |
£295,035,882 |
17 Jan 2019 |
| NHS England - Midlands and East Branded Medicines - Tranche B shared |
NHS England |
£295,035,882 |
17 Jan 2019 |
| NHS England - Midlands and East Branded Medicines - Tranche B shared |
NHS England |
£295,035,882 |
17 Jan 2019 |
| NHS England - Midlands and East Branded Medicines - Tranche B shared |
NHS England |
£295,035,882 |
17 Jan 2019 |
| NHS National Framework Agreement for the Supply of Adalimumab shared |
NHS England |
£159,371,013 |
1 Dec 2018 |
| NHS England Framework Agreement - London - Tranche A shared |
NHS England |
£211,435,404 |
15 Aug 2018 |
| NHS Framework Agreement for Trastuzumab Injection shared |
NHS England |
£226,961,206 |
16 Jul 2018 |
Top buyers
By number of awards. Value is the total of awards made to this supplier alone outside frameworks, excluding VAT where the notices give it.